Sivik Global Healthcare’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sivik Global Healthcare’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,000	Closed	-$1.19M	–	35
2025 Q4	$1.19M	Buy	+3,000	New	+$1.33M	0.35%	49
2025 Q3	–	Sell	-6,500	Closed	-$2.12M	–	46
2025 Q2	$2.12M	Buy	+6,500	New	+$1.8M	0.58%	43
2025 Q1	–	Sell	-7,000	Closed	-$1.65M	–	34
2024 Q4	$1.65M	Buy	+7,000	New	+$1.84M	0.87%	34
2023 Q3	–	Sell	-8,000	Closed	-$1.52M	–	35
2023 Q2	$1.52M	Buy	8,000 +500	+7%	+$99.1K	0.36%	39
2023 Q1	$1.5M	Buy	+7,500	New	+$1.58M	0.65%	40

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sivik Global Healthcare's ALNY Position: Q1 2026 in Review

Sivik Global Healthcare sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,000 shares — an estimated $1.19M sold.

Sivik Global Healthcare first reported a position in ALNY in Q1 2023 and held it in 5 quarters. The position peaked at $2.12M in Q2 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Sivik Global Healthcare reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sivik Global Healthcare sold 3,000 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.19M.
Sivik Global Healthcare first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 5 quarters.
Sivik Global Healthcare's Alnylam Pharmaceuticals position peaked at $2.12M in Q2 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Sivik Global Healthcare's 13F filing for Q1 2026, filed 15 Apr 2026.